Literature DB >> 10905362

Comparison of the efficacy of 400mg and 800mg of clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection in a Japanese population.

H Miwi1, T Murai, K Sato, R Ohkura, T Yamada, A Nagahara, K Ohtaka, T Minowa, A Kurosawa, N Sato.   

Abstract

We conducted a randomized prospective comparative study to determine whether a 1-week lansoprazole-amoxicillin-clarithromycin (LAC) regimen with 800 mg of clarithromycin a day was more effective such a regimen with 400 mg daily in the Japanese population. One hundred and seventy-five Helicobacter pylori-positive patients were randomly assigned to receive one of two different 7-day regimens, one with clarithromycin 400 mg (LAC 400 regimen) and the other with clarithromycin 800 mg (LAC 800 regimen). The cure rates for both regimens were similar, although adverse effects were significantly more frequent in the LAC 800 regimen, suggesting that 400 mg of clarithromycin may be sufficient in our patient population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10905362     DOI: 10.1007/s005350070077

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  4 in total

1.  Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis.

Authors:  H Miwa; H Misawa; T Yamada; A Nagahara; K Ohtaka; N Sato
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

2.  Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection.

Authors:  Josip Bago; Anita Galović; Zeljka Belosić Halle; A Bilić; M Bevanda; Petra Bago
Journal:  Wien Klin Wochenschr       Date:  2004-07-31       Impact factor: 1.704

3.  Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan.

Authors:  Kazunari Murakami; Takahisa Furuta; Takashi Ando; Takeshi Nakajima; Yoshikatsu Inui; Tadayuki Oshima; Toshihiko Tomita; Katsuhiro Mabe; Makoto Sasaki; Takanori Suganuma; Hideyuki Nomura; Kiichi Satoh; Shinichiro Hori; Syuuji Inoue; Takeshi Tomokane; Mineo Kudo; Tomoki Inaba; Susumu Take; Toshifumi Ohkusa; Shojiro Yamamoto; Shigeaki Mizuno; Toshiro Kamoshida; Kenji Amagai; Junichi Iwamoto; Jun Miwa; Masaaki Kodama; Tadayoshi Okimoto; Mototsugu Kato; Masahiro Asaka
Journal:  J Gastroenterol       Date:  2013-01-11       Impact factor: 7.527

4.  Cost Analysis in Helicobacter pylori Eradication Therapy Based on a Database of Health Insurance Claims in Japan.

Authors:  Kengo Tokunaga; Chihiro Suzuki; Miyuki Hasegawa; Ikuo Fujimori
Journal:  Clinicoecon Outcomes Res       Date:  2021-04-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.